Fig 1: Differential role of NID1 in the extracellular and intracellular domains for TRAMP prostate tumor cells. The single and double asterisks indicate p < 0.05 and 0.01, respectively. (a) Extracellular NID1 as a tumor suppressor by downregulating TGFβ and upregulating c-cas3 for apoptosis induction and p53 for tumor suppression. (b and c) Reduction in EdU-based proliferation and scratch-based motility of TRAMP cells by extracellular NID1. (d and e) Elevation in the EdU-based proliferation and scratch-based migration of TRAMP cells by the overexpression of NID1. (f) Upregulation of TGFβ and Snail, and downregulation of c-cas3 in TRAMP cells by the overexpression of NID1. (g and h) Downregulation of TGFβ and Snail, and upregulation of c-cas3 in TRAMP cells by the overexpression of PRSS8 and PVRL2.CN, control; c-cas3, cleaved caspase 3; NID1, nidogen 1; TGFβ, transforming growth factor beta.
Fig 2: Antitumor effects of PRSS8, PVRL2, and NID1 on TRAMP prostate tumor cells. The single and double asterisks indicate p < 0.05 and 0.01, respectively. (a) Elevated levels of PRSS8, PVRL2, and NID1 in the urine samples from the post-prostatectomy patients. (b and c) Downregulation of TGFβ, and upregulation of c-cas3 and p53 by the incubation of TRAMP prostate tumor cells with 1, 2 µg/mL of PRSS8 and PVRL2. (d and e) Reduction in the EdU-based proliferation and scratch-based migration of TRAMP cells by PRSS8 recombinant proteins. (f and g) Reduction in the EdU-based proliferation and scratch-based migration of TRAMP cells by PVRL2 recombinant proteins.c-cas3, cleaved caspase 3; CN, control; NID1, nidogen 1; PRSS8, prostasin; PVRL2, poliovirus receptor-related 2 or nectin 2; TGFβ, transforming growth factor beta.
Fig 3: Prediction of the potential tumor suppressors in the urine samples from the post-prostatectomy patients. The single and double asterisks indicate p < 0.05 and 0.01, respectively. (a) List of 41 potential tumor suppressors that were significantly enriched in the urine samples from the post-prostatectomy patients. (b) MTT-based cell viability of TRAMP prostate tumor cells, and 4T1.2 and EO771 mammary tumor cells in response to 19 recombinant proteins at 5 µg/mL. Three proteins (PRSS8, PVRL2, and NID1) were selected for further analysis. (c–e) Concentrations of prostasin (PRSS8), nectin 2 (PVRL2), and NID1 in urine from the pre and post-prostatectomy patients.NID1, nidogen 1.
Fig 4: Tumor selectivity, effects on percent survival, and the putative regulatory mechanism. (a) Tumor selectivity. The tumor selectivity was defined as the ratio of ‘reduction in MTT-based viability of tumor cells’ to ‘reduction in MTT-based viability of non-tumor cells’. The double asterisk indicates p < 0.01. Two tumor cell lines (TRAMP and PC-3 cells) and three non-tumor cell lines (A5, adipose, and MC3T3 cells) were employed. Of note, N.D. means that the viability of non-tumor cells was stimulated. (b–d) Percent survival of all cancer patients with the low and high mRNA levels of PRSS8, PVRL2, and NID1. (e) Putative tumor-suppressing mechanism by urine from the post-prostatectomy patients.NID1, nidogen 1; PSA, prostate-specific antigen.
Supplier Page from R&D Systems, a Bio-Techne Brand for Recombinant Human Prostasin/Prss8 Protein, CF